Editor LSA

Stocks in Focus: Vical Incorporated (NASDAQ:VICL), Generex Biotechnology Corporation (OTCMKTS:GNBT), Nektar Therapeutics (NASDAQ:NKTR), Affymetrix, Inc. (NASDAQ:AFFX)

 

Lewes, DE -- (SBWIRE) -- 09/11/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Vical Incorporated (NASDAQ:VICL), Generex Biotechnology Corporation (OTCMKTS:GNBT), Nektar Therapeutics (NASDAQ:NKTR), Affymetrix, Inc. (NASDAQ:AFFX)

Vical Incorporated (NASDAQ:VICL) opened its shares at the price of $1.24 for the day. Its closing price was $1.23 after losing -0.81% for the day. The company traded with the total volume of 1.38 million shares, while its average trading volume remained 3.36 million shares. The beta of VICL stands at1.74.

Where VICL is Headed Exactly? Find out in This Trend Analysis Reports

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Generex Biotechnology Corporation (OTCMKTS:GNBT) percentage change surged 1.59% to close at $0.0320 with the total traded volume of 1.36 million shares, and average volume of 2.46 million. The 52 week range of the stock remained $0.02 - $0.09, while its day lowest price was $0.03 and it hit its day highest price at $0.03.

Can GNBT Show a Strong Recovery? Find out in This Research Report

Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.

Nektar Therapeutics (NASDAQ:NKTR) started its trading session with the price of $13.44 and closed at $13.78 by scoring +2.99%. NKTR’s stocks traded with total volume of 1.34 million shares, while the average trading volume remained 1.16 million shares. The beta of NKTR stands at 0.64. Day range of the stock was $13.10 -$13.80.

Should NKTR a Buy or Sell Now? Find Out Here

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms.

Affymetrix, Inc. (NASDAQ:AFFX) ended its day with the loss of -1.59% and closed at the price of $6.20 after opening at $6.36. Stock traded during its last trading session with the total volume of 1.33 million shares, as compared to its average volume of 1.43 million shares.

What AFFX’s Charts Are Signaling for Traders? Find Out Here

Affymetrix, Inc. provides life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, and Asia.

About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.

Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/